Depo-Provera Settlement Calculator 2026: Estimating a Depo-Provera Lawsuit Payout Amount
Trying to gauge a possible Depo-Provera lawsuit payout amount? This free Depo-Provera settlement calculator helps you organize the details that matter after repeated Depo-Provera or depot medroxyprogesterone acetate (DMPA) shots and a later meningioma diagnosis: your injection history, treatment, neurological effects, medical records, lost wages and other losses.
- Lays out your injection history and the timing of diagnosis.
- Records surgery, radiation, monitoring and neurological effects.
- Points out missing medical, pharmacy, wage and damages records.
- Keeps official legal and medical facts apart from editorial settlement estimates.
Estimate Your Depo-Provera Claim
Work through the guided questions using your injection history, diagnosis, treatment, neurological symptoms, medical bills and other documented losses.
Essential Facts About Depo-Provera Meningioma Claims
Federal Depo-Provera product liability cases are consolidated as MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida. The JPML's August 3, 2026 report shows 6,294 pending actions and 6,394 historical actions.
Federal MDL Underway
MDL 3140 handles shared pretrial questions, while each plaintiff keeps an individual claim and individual damages.
MDL 3140 court page →6,294 Pending Actions
The JPML's report dated August 3, 2026 counts 6,294 pending actions in MDL 3140.
JPML pending MDL reports →FDA Label Warning on Meningioma
Current FDA-approved prescribing information notes that meningiomas have been reported after repeated doses, mostly with long-term use.
FDA label →Research Continues
Several observational studies link injectable medroxyprogesterone acetate to higher meningioma risk, especially with longer use.
See the studies →Who May Qualify for a Depo-Provera Claim Review?
This page cannot decide eligibility. Attorneys looking at a possible claim may consider the type and length of DMPA use, when the diagnosis came, tumor type and location, treatment, medical proof, other risk factors, damages, defendants and the applicable deadline.
Facts That May Support a Review
- Documented Depo-Provera or DMPA injections before the diagnosis
- An intracranial meningioma confirmed by imaging or pathology
- Extended or repeated injections shown in pharmacy, clinic or insurance records
- Surgery, radiation, neurological symptoms, monitoring or future care needs
- Documented medical bills, lost wages, disability or effects on quality of life
Issues That Need Closer Analysis
- Uncertain injection dates or product
- A diagnosis that predates use of the drug
- Tumor type not clearly recorded as an intracranial meningioma
- Gaps in imaging, pathology, pharmacy or provider records
- Questions about the statute of limitations, jurisdiction or other deadlines
Illustrative Depo-Provera Lawsuit Payout Ranges
These ranges are Legal Lawsuit editorial planning estimates drawn from injury severity, treatment burden, neurological effects, proof of use and documented losses. They are not official averages, a court-approved grid, settlement offers or guaranteed amounts.
Severe or Permanently Disabling Injury
$750,000–$1.5M+Complex surgery, radiation, recurrence, lasting neurological deficits, extensive future care, large wage losses or well-documented impairment.
Editorial estimate by Legal Lawsuit only; actual results may be lower, higher or nothing.Surgery or Moderate-Impact Injury
$300,000–$750,000Major surgery or treatment, ongoing symptoms, recovery limits, lost income, continued monitoring and solid proof of use.
Editorial estimate by Legal Lawsuit only; not an official tier.Confirmed Diagnosis With Lighter Treatment
$100,000–$300,000A confirmed meningioma managed by monitoring or relatively limited treatment, with smaller financial losses, fewer lasting symptoms or less complete records.
Editorial estimate by Legal Lawsuit only; not a forecast of compensation.Research on Depo-Provera, Medroxyprogesterone Acetate and Meningioma
The science has moved fast. These studies are observational and offer population-level evidence, not a diagnosis or a causation finding for any individual.
2024 BMJ National Case-Control Study (France)
This French national study found an odds ratio of 5.55 linking injectable medroxyprogesterone acetate to intracranial meningioma requiring surgery, with the added risk driven by use lasting a year or more.
View on PubMed →U.S. Population-Based Study
A retrospective U.S. cohort study reported a relative risk of 2.43 for a meningioma diagnosis among DMPA users versus controls, with greater risk tied to longer exposure.
View on PubMed →2026 Danish Population Study
A Danish case-control study found an odds ratio of 4.55 for injectable medroxyprogesterone and new meningioma, adding further population-level data.
View on PubMed →Records That Strengthen a Depo-Provera Claim Review
The calculator works best when your answers come from documents rather than memory.
- Injection records with dates
- Pharmacy, OB-GYN, clinic or insurer records showing use
- MRI or CT scans confirming the meningioma
- Pathology, neurology, oncology or neurosurgery notes
- Records of craniotomy, radiation and hospital stays
- Documentation of seizures, vision or hearing changes, headaches or cognitive effects
- Medical bills and out-of-pocket costs
- Proof of lost income and employment
- Disability, caregiving and rehab records
- Recommendations for future treatment or monitoring
- A dated timeline from first injection to diagnosis
- Evidence of how the condition affected daily life and work
Where MDL No. 3140 Stands
MDL 3140 is pending before Judge M. Casey Rodgers in the Northern District of Florida. An MDL coordinates shared pretrial work such as discovery and expert issues and is not a class action. In 2026 Pfizer and plaintiffs' leadership announced a global agreement in principle (June) followed by a Master Settlement Agreement (July) for eligible claims, with a court-appointed administrator handling registration; check current program deadlines with an attorney.
What Affects a Depo-Provera Lawsuit Payout Amount?
1. Injection History
How long and how often you received injections, dosing records and reliable proof of use shape the exposure analysis.
2. Tumor Characteristics
Tumor location, size, recurrence, grade, symptoms and prognosis influence treatment burden and damages.
3. Surgery & Treatment
Craniotomy, radiation, hospital care, rehabilitation, monitoring and future treatment can significantly affect losses.
4. Neurological Effects
Documented problems with vision, hearing, seizures, balance, cognition or other neurological functions may increase damages.
5. Economic Loss
Medical costs, lost income, reduced earning ability, disability and caregiving expenses add to documented damages.
6. Legal and Evidence Risks
Causation rulings, expert evidence, jurisdiction, deadlines, defendants and alternative explanations can affect settlement leverage.
How This Depo-Provera Calculator Works
The tool arranges your claim details into an early educational model. It does not apply a single universal multiplier and cannot replace medical, legal or records review.
1. Show Product Use
Enter how long you received injections and the best records you have showing Depo-Provera or DMPA use before diagnosis.
2. Add Diagnosis and Treatment
Use imaging, pathology, surgery, radiation, monitoring and neurological details whenever possible.
3. Add Damages
Include medical bills, lost wages, disability, future care, treatment burden and other documented losses.
Filing Deadlines for Depo-Provera Lawsuits
No single nationwide statute of limitations covers every Depo-Provera claim. Deadlines can depend on state law, the diagnosis date, discovery rules, earlier proceedings, defendant-specific issues and other facts.
More Depo-Provera and Settlement Resources
Depo-Provera Calculator FAQs
What does the Depo-Provera calculator estimate?
It turns your product use, meningioma diagnosis, treatment, neurological effects and losses into an educational value range, not a prediction of an actual settlement.
Is there an average Depo-Provera settlement amount?
No dependable average fits an individual claim. Current projected ranges are editorial models, not a court-approved payout schedule.
How many Depo-Provera cases are pending in MDL 3140?
According to the JPML's August 3, 2026 report, 6,294 actions are pending, a figure that shifts as cases are filed, transferred, dismissed or resolved.
Does the Depo-Provera label warn about meningioma?
Yes. Since a December 2025 revision, the prescribing information includes a meningioma warning noting reports after repeated doses, mainly with long-term use.
Does the research prove Depo-Provera caused my tumor?
No population study can settle that for one person. Medical causation requires a medical and legal analysis of your specific claim.
Does using the calculator make me an attorney's client?
No. Using this site or tool does not create an attorney-client relationship; representation requires a licensed attorney's acceptance and a signed engagement agreement.
Get a Free Depo-Provera Case Review
If you were diagnosed with a meningioma after using Depo-Provera, use the calculator to organize your records or request a free, confidential case review.
Sources on Depo-Provera Litigation, the FDA Label and Medical Research
Northern District of Florida: MDL 3140
The official case page with hearing dates, court filings and master docket details.
View the court page →JPML: Report Dated August 3, 2026
The official monthly report showing 6,294 pending actions in MDL 3140.
View JPML pending MDL reports →FDA: Depo-Provera CI Prescribing Information
The December 2025 federal label, including the meningioma warning and instructions on monitoring and stopping the drug.
View the FDA label →BMJ / PubMed: 2024 Study
A French national case-control study of certain progestogens and intracranial meningioma requiring surgery.
View on PubMed →U.S. DMPA Study
U.S. population research on depot medroxyprogesterone acetate and later meningioma diagnoses.
View on PubMed →2026 Danish Contraceptive Study
Population case-control research on contraceptive progestogens and new meningiomas.
View on PubMed →
